Experimental drug cocktail targets relapsed leukemia
NCT ID NCT04666649
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested a combination of two drugs, pegcrisantaspase and venetoclax, in 27 adults whose acute myeloid leukemia had come back or not responded to standard treatments. The main goal was to find safe doses and check for side effects. Researchers also looked at whether the treatment could lead to remission.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Pegcrisantaspase and venetoclax
- What this could lead to
- If successful, this combination could offer a new treatment option for patients with hard-to-treat acute myeloid leukemia.
- What could go wrong
- This is a very early Phase 1 trial with only 27 participants, focused on safety and dosing. It may not lead to an effective treatment, and side effects could be significant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Greenebaum Cancer Center at University of Maryland Medical Center
Baltimore, Maryland, 21201, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.